Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II: Erratum

In the article beginning on page 949 in the June 2018 issue of Critical Care Medicine, there were several errors.

1. Figure 1 – Survival through day 28

   Replaced: HR 0.515 (0.304, 0.817)

   With: HR 0.515 (0.304, 0.871)

2. Page 952, Outcomes

   Added: Using cumulative incidence estimates to adjust for death as a competing risk, patients in the Ang II group were more likely to discontinue RRT within 7 days (unadjusted HR, 2.90; 95%, 1.29–6.52; p = 0.007)

   Supplemental digital content data corrections:

3. Supplemental Table 5 – Summary of post-hoc analysis baseline demographics and disease characteristics

   Replaced: Screening mean arterial pressure (mmHg), placebo median (IQR) 65.4 (68.9-67.5)

   With: Screening mean arterial pressure (mmHg), placebo median (IQR) 65.4 (61.9–67.5)

4. Supplemental Table 7 – Mean norepinephrine equivalent dose (μg/kg/min)

   Deleted superfluous data (last row):